tenofovir has been researched along with Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Chao, Y; Hou, MC; Huang, YH; Lan, KH; Lee, IC; Li, CP; Lin, HC; Su, CW | 2 |
| Behrendt, H; Bieda, A; Leśniak, K; Niemczyk, S | 1 |
| Beumer, JH; Chaphekar, N; Chu, E; Guo, J; Jones, R; Joshi, A; Kiesel, BF; Kunos, CA; Taylor, S; Venkataramanan, R | 1 |
| Chang, KC; Chen, CH; Chou, YP; Hu, TH; Hung, CH; Kuo, MT; Kuo, YH; Lu, SN; Tsai, MC; Tseng, PL; Wang, JH | 1 |
| Chang, CY; Chen, TB; Hsu, YC; Lin, JT; Mo, LR; Tseng, CM | 1 |
| Kast, RE | 1 |
7 other study(ies) available for tenofovir and Neoplasms
| Article | Year |
|---|---|
Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy.
Topics: Acute Kidney Injury; Adenine; Alanine; Antiviral Agents; Cisplatin; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney; Neoplasms; Retrospective Studies; Tenofovir; Treatment Outcome | 2022 |
Severe skeletal damage suggesting neoplastic disease as a manifestation of tenofovir-induced Fanconi syndrome in chronic hepatitis B.
Topics: Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Neoplasms; Tenofovir | 2023 |
In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.
Topics: Cells, Cultured; Chemoradiotherapy; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inducers; Drug Evaluation, Preclinical; Drug Interactions; Emtricitabine; Hepatocytes; Humans; Inactivation, Metabolic; Microsomes, Liver; Neoplasms; Primary Cell Culture; Pyridines; Radiation-Sensitizing Agents; Tandem Mass Spectrometry; Tenofovir; Thiosemicarbazones | 2020 |
Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Topics: Adult; Aged; Biomarkers; Female; Follow-Up Studies; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Predictive Value of Tests; Recurrence; Secondary Prevention; Tenofovir; Time Factors | 2018 |
Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Humans; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Risk Assessment; Tenofovir | 2018 |
Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Cytotoxins; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Neoplasms; Retrospective Studies; Telbivudine; Tenofovir; Thymidine; Virus Activation; Young Adult | 2016 |
Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.
Topics: Adenine; Adenylyl Cyclases; Anti-HIV Agents; Cell Division; Cyclooxygenase Inhibitors; Humans; Hydroxyurea; Immunotherapy; Lipoxygenase Inhibitors; Lymphocytes; Neoplasms; Organophosphonates; Organophosphorus Compounds; Tenofovir; Tumor Necrosis Factor-alpha; Up-Regulation | 2003 |